Analysis of the correlation between Guillain-Barré and post-COVID-19 syndromes
DOI:
https://doi.org/10.31686/ijier.vol10.iss12.4003Keywords:
Guillain-Barré syndrome, Demyelinating Diseases, COVID-19Abstract
OBJECTIVE: To correlate Guillain-Barré as a consequence of the Post-COVID-19 syndrome, evaluating the pathophysiological, immunogenic and epidemiological mechanisms. METHODOLOGY: A systematic review was carried out, with secondary data, using articles published in the following databases: Latin American Caribbean Literature on Science and Health (LILACS), Scientific Electronic Library (ScIELO) and Pubmed; using the descriptors: Guillain-Barré syndrome; Demyelinating Diseases and COVID-19, using the Boolean operator “AND”, swapping between them. RESULTS AND DISCUSSION: According to Abu-Rumeileh et al. (2021), patients with COVID-19, even if asymptomatic, were more likely to develop GBS, with a predominance of the male population, in the classic sensorimotor form and in acute inflammatory demyelinating polyneuropathy, with an increase in pediatric cases also being observed, due to of the wide age range of Sars-Cov-2. The post-infection immune-mediated pathophysiological mechanism observed some predisposing factors, namely: neurological symptoms after Sars-Cov-2 infection, improvement of the clinical picture of GBS with immunomodulators and absence of viral RNA in the cerebrospinal fluid. CONCLUSION: Guillain-Barré Syndrome consists of an immune-mediated neuromuscular condition usually subsequent to an infectious process, which triggers an inflammatory response followed by a molecular mimicry that causes an autoimmune response in the individual's peripheral nervous system. Although there is no consensus in the scientific community regarding the causal relationship between COVID-19 and GBS, it is believed that infection with the new coronavirus precipitates an immune-mediated reaction that triggers this neuromuscular condition characterized by progressive, symmetrical and ascending weakness, in addition to areflexia.
Downloads
References
Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., & Otto, M. (2020). Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology, 269(4). https://doi.org/10.1007/s00415-020-10124-x DOI: https://doi.org/10.1007/s00415-020-10124-x
Aladawi, M., Elfil, M., Abu-Esheh, B., Abu Jazar, D., Armouti, A., Bayoumi, A., & Piccione, E. (2022). Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 49(1), 38–48. https://doi.org/10.1017/cjn.2021.102 DOI: https://doi.org/10.1017/cjn.2021.102
Caress, J. B., Castoro, R. J., Simmons, Z., Scelsa, S. N., Lewis, R. A., Ahlawat, A., & Narayanaswami, P. (2020). COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & Nerve, 62(4). https://doi.org/10.1002/mus.27024 DOI: https://doi.org/10.1002/mus.27024
Collantes, M. E. V., Espiritu, A. I., Sy, M. C. C., Anlacan, V. M. M., & Jamora, R. D. G. (2020). Neurological manifestations in COVID-19 infection: A systematic review and meta-analysis. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 1–26. https://doi.org/10.1017/cjn.2020.146 DOI: https://doi.org/10.1017/cjn.2020.146
D, V., Sharma, A., Kumar, A., & Flora, S. J. S. (2021). Neurological Manifestations in COVID-19 Patients: A Meta-Analysis. ACS Chemical Neuroscience, 12(15), acschemneuro.1c00353. https://doi.org/10.1021/acschemneuro.1c00353 DOI: https://doi.org/10.1021/acschemneuro.1c00353
Dalakas, M. C. (2020). Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurology - Neuroimmunology Neuroinflammation, 7(5). https://doi.org/10.1212/NXI.0000000000000781 DOI: https://doi.org/10.1212/NXI.0000000000000781
De Sanctis, P., Doneddu, P. E., Viganò, L., Selmi, C., & Nobile‐Orazio, E. (2020). Guillain Barré Syndrome associated with SARS‐CoV‐2 infection. A Systematic Review. European Journal of Neurology. https://doi.org/10.1111/ene.14462 DOI: https://doi.org/10.1111/ene.14462
FINSTERER, J., SCORZA, F. A., SCORZA, C. A., & FIORINI, A. C. (2021). Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit. Arquivos de Neuro-Psiquiatria, 79. https://doi.org/10.1590/0004-282x-anp-2021-0030 DOI: https://doi.org/10.1590/0004-282x-anp-2021-0030
Freire, M., Andrade, A., Sopeña, B., & Lopez-Rodriguez, M. (2021). Guillain Barré syndrome associated with COVID-19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review. Autoimmunity Reviews, 20(8), 102875. https://doi.org/10.1016/j.autrev.2021.102875 DOI: https://doi.org/10.1016/j.autrev.2021.102875
Gittermann, L. M. T., Feris, S. N. V., & Giacoman, A. von O. (2020). Relation between COVID-19 and Guillain-Barré syndrome in adults: a systematic review. Neurología (English Edition), 35(9), 646–654. https://doi.org/10.1016/j.nrleng.2020.07.005 DOI: https://doi.org/10.1016/j.nrleng.2020.07.005
Hasan, I., Saif-Ur-Rahman, K. M., Hayat, S., Papri, N., Jahan, I., Azam, R., Ara, G., & Islam, Z. (2020). Guillain-Barré syndrome associated with SARS-CoV-2 infection: A systematic review and individual participant data meta-analysis. Journal of the Peripheral Nervous System: JPNS, 25(4), 335–343. https://doi.org/10.1111/jns.12419 DOI: https://doi.org/10.1111/jns.12419
Koike, H., Chiba, A., & Katsuno, M. (2021). Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review. Neurology and Therapy, 25(2). https://doi.org/10.1007/s40120-021-00261-4 DOI: https://doi.org/10.1007/s40120-021-00261-4
Kulikowska, J., Kulczyńska-Przybik, A., Mroczko, B., & Kułakowska, A. (2021). The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis—A Literature Review. International Journal of Molecular Sciences, 22(11), 5894. https://doi.org/10.3390/ijms22115894 DOI: https://doi.org/10.3390/ijms22115894
Mohamadian, M., Chiti, H., Shoghli, A., Biglari, S., Parsamanesh, N., & Esmaeilzadeh, A. (2021). COVID‐19: Virology, biology and novel laboratory diagnosis. The Journal of Gene Medicine, 23(2). https://doi.org/10.1002/jgm.3303 DOI: https://doi.org/10.1002/jgm.3303
Palaiodimou, L., Stefanou, M., Katsanos, A. H., Fragkou, P. C., Papadopoulou, M., Moschovos, C., Michopoulos, I., Kokotis, P., Bakirtzis, C., Naska, A., Vassilakopoulos, T. I., Chroni, E., Tsiodras, S., & Tsivgoulis, G. (2021). Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis. European Journal of Neurology, 28(10), 3517–3529. https://doi.org/10.1111/ene.14860 DOI: https://doi.org/10.1111/ene.14860
Paliwal, V. K., Garg, R. K., Gupta, A., & Tejan, N. (2020). Neuromuscular presentations in patients with COVID-19. Neurological Sciences, 41(11), 3039–3056. https://doi.org/10.1007/s10072-020-04708-8 DOI: https://doi.org/10.1007/s10072-020-04708-8
Patnaik, U. J. (2021). Review article on COVID-19 and Guillain-Barré syndrome. Frontiers in Bioscience, 13(1), 97. https://doi.org/10.52586/s555 DOI: https://doi.org/10.52586/S555
Peña, S. L., Bello Quezada, M. E., & Segura Lemus, V. (2021). Manifestaciones Neurológicas y COVID-19. Alerta, Revista Científica Del Instituto Nacional de Salud, 4(2), 69–80. https://doi.org/10.5377/alerta.v4i2.9772 DOI: https://doi.org/10.5377/alerta.v4i2.9772
Sansone, P., Giaccari, L. G., Aurilio, C., Coppolino, F., Esposito, V., Fiore, M., Paladini, A., Passavanti, M. B., Pota, V., & Pace, M. C. (2021). Post-Infectious Guillain–Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life, 11(2), 167. https://doi.org/10.3390/life11020167 DOI: https://doi.org/10.3390/life11020167
Sheikh, A. B., Chourasia, P. K., Javed, N., Chourasia, M. K., Suriya, S. S., Upadhyay, S., Ijaz, F., Pal, S., Moghimi, N., & Shekhar, R. (2021). Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review. Journal of Neuroimmunology, 355, 577577. https://doi.org/10.1016/j.jneuroim.2021.577577 DOI: https://doi.org/10.1016/j.jneuroim.2021.577577
Shoraka, S., Ferreira, M. L. B., Mohebbi, S. R., & Ghaemi, A. (2021). SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.674922 DOI: https://doi.org/10.3389/fimmu.2021.674922
Tawakul, A. A., Al-Doboke, A. W., Altayyar, S. A., Alsulami, S. A., Alfahmi, A. M., & Nooh, R. T. (2021). Guillain-Barré Syndrome in the COVID-19 Pandemic. Neurology International, 14(1), 34–48. https://doi.org/10.3390/neurolint14010003 DOI: https://doi.org/10.3390/neurolint14010003
Uncini, A., Vallat, J.-M., & Jacobs, B. C. (2020). Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. Journal of Neurology, Neurosurgery & Psychiatry, 91(10), 1105–1110. https://doi.org/10.1136/jnnp-2020-324491 DOI: https://doi.org/10.1136/jnnp-2020-324491
Velavan, T. P., & Meyer, C. G. (2020). The COVID‐19 epidemic. Tropical Medicine & International Health, 25(3), 278–280. https://doi.org/10.1111/tmi.13383 DOI: https://doi.org/10.1111/tmi.13383
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Matheus Lopes Martins, Sabrina Carvalho Melo , Amanda de Brito Silva, Luan Kelves Miranda de Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyrights for articles published in IJIER journals are retained by the authors, with first publication rights granted to the journal. The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author for more visit Copyright & License.
How to Cite
Accepted 2022-10-24
Published 2022-12-01
